EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023

Invite Credit Card Holder to pay

Requester Details

Credit Card Holder Details

Company Details

Message to be included

Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection.

CLL is the most common form of leukemia in the western world, with an average annual incidence of 5.0 per 100,000 population in people of all ages. CLL is primarily a disease of the elderly population, with less than 10% of the cases below 40 years of age.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of CLL in the 6MM, from 37,795 diagnosed incident cases in 2013 to 45,683 diagnosed incident cases in 2023, with an annual growth rate (AGR) of 2.09% during the forecast period. The 5-year diagnosed prevalent cases of CLL in the 6MM increased from 150,800 diagnosed prevalent cases in 2013 to 183,165 diagnosed prevalent cases in 2023, with an AGR of 2.15% during the forecast period.

GlobalData’s epidemiological forecast for the diagnosed incident and 5-year diagnosed prevalent cases of CLL in the 6MM is supported by age- and sex-specific data for incidence and 1- to 5-year relative survival data used for the 5-year diagnosed prevalent cases forecast are supported by country-specific, population-based studies that are nationally representative of the entire population in the respective markets. The diagnosed incident cases of CLL in each of the 6MM were further segmented by Rai stage at diagnosis to provide a more detailed analysis of the patient population, as Rai stage at diagnosis is an important factor for predicting the prognosis and treatment modalities for CLL at different stages.

Scope

The Chronic lymphocytic leukemia (CLL) EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and the global and historical trends for CLL in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, the report also includes a 10-year epidemiological forecast of the diagnosed incident cases of CLL segmented by age (beginning at 40 years and ending at 80 years and older) and sex. GlobalData epidemiologists also forecast the 5-year diagnosed prevalent cases of CLL in the 6MM. Additionally, the report provides CLL diagnosed incident cases segmented by Rai stage at diagnosis for the 6MM.

The CLL epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

Develop business strategies by understanding the trends shaping and driving the global CLL market.

Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for CLL therapeutics in each of the markets covered.

Table of Contents

1Table of Contents1

1.1List of Tables2

1.2List of Figures3

2Executive Summary4

3Introduction6

3.1Catalyst6

3.2Related Reports7

3.3Upcoming Reports7

4Epidemiology7

4.1Disease ...

1Table of Contents1

1.1List of Tables2

1.2List of Figures3

2Executive Summary4

3Introduction6

3.1Catalyst6

3.2Related Reports7

3.3Upcoming Reports7

4Epidemiology7

4.1Disease Background7

4.2Risk Factors and Comorbidities9

4.3Global Trends11

4.3.1Incidence11

4.3.2Survival from CLL – US and 5EU13

4.4Forecast Methodology14

4.4.1Sources Used16

4.4.2Sources Not Used18

4.4.3Forecast Assumptions and Methods, Diagnosed Incident Cases18

4.4.4Forecast Assumptions and Methods, 5-Year Diagnosed Prevalent Cases20

4.4.5Forecast Assumptions and Methods, Rai Stage at Diagnosis20

4.5Epidemiological Forecast of CLL (2013–2023)21

4.5.1Diagnosed Incident Cases of CLL21

4.5.2Age-Specific Diagnosed Incident Cases of CLL23

4.5.3Sex-Specific Diagnosed Incident Cases of CLL24

4.5.4Age-Standardized Diagnosed Incidence of CLL26

4.5.5Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis27

4.5.65-Year Diagnosed Prevalent Cases of CLL28

4.6Discussion30

4.6.1Epidemiological Forecast Insight30

4.6.2Limitations of the Analysis31

4.6.3Strengths of the Analysis31

5Appendix32

5.1Bibliography32

5.2About the Authors35

5.2.1Epidemiologists35

5.2.2Reviewers35

5.2.3Global Director of Epidemiology and Health Policy37

5.2.4Global Head of Healthcare37

5.3About GlobalData37

5.4About EpiCast38

5.5Contact Us38

5.6Disclaimer39

List of tables

Table 1: CLL Clinical Stages at Diagnosis9

Table 2: Risk Factors and Comorbidities for CLL10

Table 3: Trends in the Age-Adjusted Incidence of CLL in ...

Table 1: CLL Clinical Stages at Diagnosis9

Table 2: Risk Factors and Comorbidities for CLL10

Table 3: Trends in the Age-Adjusted Incidence of CLL in the US, All Ages, 2003–201012

Table 4: Trends in the Age-Adjusted Incidence of CLL(Cases per 100,000 Population) in France, All Ages, 1980–201212

Table 5: Trends in the 5-Year Relative Survival (%) of CLL in the US and 5EU, Both Sexes, 1993–200914

Table 6: Sources of Epidemiological Data Used for the Forecast for CLL Incident and Prevalent Cases, and the Rai Stage at Diagnosis14

Table 7: 6MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages =40 Years, N, 2013–202321

Table 8: 6MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, N (Row %), 201323

Table 9: 6MM, Sex-Specific Diagnosed Incident Cases of CLL, Ages =40 Years, N (Row %), 201325

Table 10: 6MM, 5-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages =40 Years, N, 2013–202328

List of figures

Figure 1: 6MM, Diagnosed Incident Cases of CLL, Ages =40 Years, Both Sexes, N, 2013 and 20235

Figure 2: 6MM, 5-Year Diagnosed Prevalent Cases of ...

Figure 1: 6MM, Diagnosed Incident Cases of CLL, Ages =40 Years, Both Sexes, N, 2013 and 20235

Figure 2: 6MM, 5-Year Diagnosed Prevalent Cases of CLL, Ages =40 Years, Both Sexes, N, 2013 and 20236

Figure 3: 6MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages =40 Years, N, 2013–202322

Figure 4: 6MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, N, 201324

Figure 5: 6MM, Sex-Specific Diagnosed Incident Cases of CLL, Ages =40 Years, N, 201325

Figure 6: 6MM, Age-Standardized Diagnosed Incidence of CLL (Cases per 100,000 Population), Ages =40 Years, by Sex, 201327

Figure 7: 6MM, Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis, Ages =40 Years, N, 201328

Figure 8: 6MM, 5-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages =40 Years, N, 2013–202329

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports